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HYPOXIA-INDUCIBLE
FACTOR-1a IN STEM CELL
PRECONDITIONING:
MECHANISTIC ROLE OF
HYPOXIA-RELATED MICRO-
RNAS
To the Editor:
Since its inception more than 2 de-
cades ago, ischemic preconditioning
(IP) is considered as the most powerful
cytoprotective stimulus and is being
devised as a potent strategy to promote
stem cell survival post-engraftment in
the infarcted heart.1 The elegant study
from Hu and colleagues2 is a step for-
ward toward the use of low oxygen cul-
ture conditions to trigger activation of
survival signaling pathways in the cells
before their engraftment in vivo. The
authors showed significantly improved
survival of the hypoxia-treated (0.5%
oxygen for 24 hours) mesenchymal
stem cells after engraftment in the in-
farcted heart. Unlikemany of the previ-
ous studies, an important aspect of the
study protocol was cell engraftment
during the acute phase of myocardial
infarction to assess the effectiveness
of a preconditioning approach. Acute
phase engraftment exposed the en-
grafted cells to the harsh, cytokine-
rich microenvironment of the infarcted
myocardium, which was aggravated
even more because of the infiltration
of inflammatory and progenitor cells
as a part of the intrinsic repair
process. The authors attributed the
effectiveness of the hypoxic precondi-
tioning approach to up-regulation of
hypoxia inducible factor (HIF)-1a, a
heterodimeric master switch of a
hypoxia-responsive array of genes
that enable the cells to acclimatize
and survive in low oxygen conditions.
Although a low-level presence of
HIF-1a has been reported in the cyto-
plasmic compartment of cells grown
under normoxia, hypoxia stabilizes
HIF-1a against degradation and pro-
motes its translocation to the nucleus,
where it forms functional complexes
for gain of functions. As a part of our
continuing endeavor to precondition
donor cells for their better survival in
the infarcted heart and that too with
clinical relevance,3 we share our expe-
rience of extrapolating the classic IP
strategy of exposing the cells to multi-
ple sublethal ischemia/reoxygenation
cycles of short duration to promote
mesenchymal stem cell survival
(unpublished data). This approach rep-
resents an extension of the one-time,
long-term exposure to sublethal
hypoxia approach suggested by Hu
and colleagues.2 Our results showed
significant up-regulation of HIF-1a in
an Akt-dependent manner in the cells
preconditioned by 2 cycles of ische-
mia-reperfusion of 30 minutes each.
These molecular events successfully
attenuated donor cell attrition on subse-
quent exposure to lethal ischemic
insult. The participation of hypoxia-
associated micro RNAs (miR), miR-
107 and miR-210,4 downstream of
HIF-1a in translation of cytoprotective
effects of IP was another important
observation in our study. HIF-1a–
specific RNA interference abrogated
both miR-107 and miR-210 in the
preconditioned cells transfected with
HIF-1a–specific siRNA with a con-
comitant increase in preponderance of
apoptotic cells. Our in vivo experimen-
tal results in a rodent model of acute
myocardial infarction showed that
transplanted preconditioned cells sur-
vived significantly better compared
with their nonpreconditioned counter-
parts. Moreover, transplantation of
preconditioned cells promoted miR-
107 and -210 expression in the in-
farcted heart at the site of the cell graft.
These novel findings necessitate more
in-depth studies to elucidate whether
the effect of IP can be duplicated by
manipulation of the cells for hypoxia-
related miRNAs to promote donor
cell survival.
Khawaja Husnain Haider, MPharm,
PhD
Ha Won Kim, PhD
Muhammad Ashraf, PhD
Department of Pathology and
Laboratory Medicine
University of Cincinnati Medical
Center
Cincinnati, Ohio
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Letters to the Editor
The Journal of Thoracic and Cardiovascular SurgeTHE IMPLICATIONS OF
OUTCOME PREDICTORS
WHEN TRANSITIONING FROM
ARTERIALTO DOUBLE-
SWITCH SURGERY
To the Editor:
I read with great interest the fate of
the systemic ventricle after double-
switch surgery among those who had
left ventricle (LV) training.1 The
authors concluded that LV training
with pulmonary artery (PA) banding
resulted in a worse outcome after the
double-switch procedure. I would like
to add a few potential explanations
for their findings. One of the impor
tant aspects of the decline in function
can be related to the coronary circula-
tion and its aberrant network in
patients with corrected transposition
of the great arteries.2 This has beenry c Volume 138, Number 1 257
CONTEGRA AND
EXTRACARDIAC FONTAN
To the Editor:
We read with great interest the letter
to the editor by Sersar and Jamjoom1
in the Journal of November 2008, de-
scribing the use of the Contegra (Med-
tronic Inc, Minneapolis, MN) bovine
jugular vein as a possible alternative
extracardiac conduit in total cavopul-
monary connection (TCPC).
We want to emphasize our bad ex-
perience with this particular conduit
in patients undergoing the Fontan pro-
cedure, which was published in the
Journal 7 years ago.2
The only 3 patients in whom the
Contegra conduit was used for TCPC
all experienced serious complications
of conduit thrombosis; 2 of them died
and 1 survived, but with major neuro-
logic injury. The Contegra implanta-
tion was carried out at different
institutions by different surgeons.
Evidence has meanwhile accumu-
lated that thrombogenicity is indeed
an inherent characteristic of the Conte-
gra bovine jugular venous conduit.
Thrombus formation has been shown
to occur even in high-flow right ventric-
ular to pulmonary artery conditions.3,4
A fatal case of conduit thrombosis
also occurred at the authors’ institution.
Thiswas publishedbyBaslaim5 in2008
(1 of 18 patients undergoing operation
between 2002 and 2005). An ‘‘opera-
tive technical cause’’ is suggested by
the author as a possible cause.
We are looking forward to the struc-
tured clinical and echocardiographic
follow-up in their patients. For the pres-
ent,we continue todiscourage the use of
the Contegra bovine jugular vein as an
extracardiac conduit in TCPC.
Paul Schoof, MD, PhD
Tjalling Waterbolk, MD
Divisions of Cardiothoracic Surgery
University Medical Center Nijmegen
and Groningen
The Netherlands
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Letters to the Editordocumented in the literature in the con-
text of simple transposition of the great
vessels but was not discussed further in
this study. The arterial switch compo-
nent of the double-switch procedure
carries all the known risk hazards as
in any arterial switch and long-term
complications, including fatal arrhyth-
mias, neoaortic regurgitation, and left
ventricular dysfunction.3 These risks
can behigher among thosewith a single
orifice coronary artery.
Training is a relative term and is
tailored to the individual patient.
Excessive training leading to LV pres-
sures more than 75% systemic is
a well-known association with late ven-
tricular dysfunction.Although the study
states that LV pressures were 65% to
80%, it would be more informative to
the reader if the authors explained the
target pressures for the 24 patients after
PAbanding in the nontrained subgroup.
Furthermore, approximately 46% (n¼
5) of the trained subgroup had more
than 1 PA band to properly prepare the
morphologic LV (mLV) for the double
switch. It would be important to know
whether such patients’ ventricles fared
better than the application of singleton
pressure load PA banding, especially
when not all LV training is detrimental
in older patients.
It is interesting to note that the mLV/
mRV pressure ratio was similar in the
trained and nontrained groups at the
time of their anatomic repair. However,
those older patients with LV dysfunc-
tion achieved mLV/mRV pressure in
less time (436 vs 730 days) than those
without dysfunction. This may imply
that the LV was generating the same
pressure at the time of the double switch
as in those with ventricular defect phys-
iology (increased end-diastolic volume,
reduced afterload) but fared better than
in the trained group. This may illustrate
that the PA band is a confounder, whe-
reas the morphology (congenitally
corrected transposition of the great ar-
teries with small restrictive ventricular
septal defect or no ventricular septal
defect) is an independent predictor,
especially when the authors state in258 The Journal of Thoracic andTable 1 that 20% of the nontrained
group had good mLV versus 60% in
the trained group (P ¼ .04, statistically
significant). Furthermore, in support of
this is the well-known association of
worsening survival in the older infant
with transposition of the great arteries
and an intact ventricular septum after
the arterial switch compared with trans-
position of the great arteries and a ven-
tricular septal defect.4 The additional
benefit of ventricle volume load via
a systemic circulation to PA shunt to
the pressure load PA band afterload
has been described and could be of ben-
efit in corrected transposition.5 Finally,
the ventricular activation time period
(QRS) has been a strong marker of ven-
tricular function.6 The authors did not
state its respective duration for the 2
groups before and after the double
switch. I would appreciate the authors’
response based on their vast experience
when managing this unique group of
patients.
Jeffrey Shuhaiber, MD
Loyola University Stritch School of
Medicine
Maywood, Ill
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